These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 2523145)
1. Selective sparing of T suppressor cells by anti interleukin-2 receptor monoclonal antibodies (IL-2R mAbs) in vitro correlates with their therapeutic effects in vivo. Tanaka K; Turka LA; Ueda H; Diamantstein T; Milford EL; Carpenter CB; Tilney NL; Kupiec-Weglinski JW Transplant Proc; 1989 Feb; 21(1 Pt 1):475-6. PubMed ID: 2523145 [No Abstract] [Full Text] [Related]
2. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function? Tellides G; Dallman MJ; Morris PJ Transplant Proc; 1989 Feb; 21(1 Pt 1):997-8. PubMed ID: 2650306 [No Abstract] [Full Text] [Related]
3. Synergistic interactions between anti-interleukin-2 receptor (IL-2R) MAb and CyA in sensitized rat recipients of cardiac allografts. Kupiec-Weglinski JW; Sablinski T; Hancock WW; Mix CT; Tilney NL Transplant Proc; 1991 Feb; 23(1 Pt 1):285-6. PubMed ID: 1990533 [No Abstract] [Full Text] [Related]
4. Anti-interleukin-2 receptor (IL-2R) antibody against rejection of organ grafts. Kupiec-Weglinski JW; Padberg W; Uhteg LC; Towpik E; Lord RH; Ma L; Diamantstein T; Strom TB; Tilney NL Transplant Proc; 1987 Feb; 19(1 Pt 1):591-3. PubMed ID: 2978926 [No Abstract] [Full Text] [Related]
5. Interleukin 2 receptor directed therapy in rat recipients of cardiac allografts: synergistic and antagonistic interactions with the gamma interferon network. Kupiec-Weglinski JW; van der Meide P; Stunkel KG; Tanaka K; Diamantstein T; Tilney NL Transplant Proc; 1989 Feb; 21(1 Pt 1):992-3. PubMed ID: 2495637 [No Abstract] [Full Text] [Related]
6. Anti-interleukin-2 receptor monoclonal antibody therapy in rats: comparison of the effector mechanisms mediated by variant murine isotypes. Stünkel KG; Grützmann R; Diamantstein T; Kupiec-Weglinski JW; Schlumberger HD Transplant Proc; 1989 Feb; 21(1 Pt 1):1003-5. PubMed ID: 2784878 [No Abstract] [Full Text] [Related]
7. Effects of anti-IL 2 receptor monoclonal antibody and cyclosporine on IL 2 receptor-positive cells infiltrating cardiac allografts in the rat. Lord RH; Hancock WW; Colby AJ; Padberg W; Diamantstein T; Kupiec-Weglinski JW; Tilney NL Transplant Proc; 1987 Feb; 19(1 Pt 1):354-5. PubMed ID: 3079156 [No Abstract] [Full Text] [Related]
8. Mechanism of action of anti-IL-2R monoclonal antibodies. ART-18 prolongs cardiac allograft survival in rats by elimination of IL-2R+ mononuclear cells. Tanaka K; Hancock WW; Osawa H; Stunkel KG; Alberghini TV; Diamantstein T; Tilney NL; Kupiec-Weglinski JW J Immunol; 1989 Nov; 143(9):2873-9. PubMed ID: 2530281 [TBL] [Abstract][Full Text] [Related]
9. Pretreatment with cyclosporin A (CyA) and anti-interleukin 2 receptor monoclonal antibody (IL-2R MAb) abrogates the anti-idiotype response in rat recipients of cardiac allografts. Tanaka K; Kupiec-Weglinski JW; Hancock WW; Stunkel K; Diamantstein T; Tilney NL Transplant Proc; 1991 Feb; 23(1 Pt 1):281-2. PubMed ID: 1990532 [No Abstract] [Full Text] [Related]
10. Prolongation of cardiac allograft survival by suppressor T cells (Ts) generated in vitro using cyclosporine. Lenrow DA; Markmann JF; Shachner MS; Naji A Transplant Proc; 1989 Feb; 21(1 Pt 1):473-4. PubMed ID: 2523144 [No Abstract] [Full Text] [Related]
11. In vivo use of rapamycin suppresses neither IL-2 production nor IL-2 receptor expression in rat transplant model. Hamashima T; Yoshimura N; Ohsaka Y; Oka T; Stepkowski SM; Kahan BD Transplant Proc; 1993 Feb; 25(1 Pt 1):723-4. PubMed ID: 8438457 [No Abstract] [Full Text] [Related]
12. In vivo activity of mixed lymphocyte response-generated suppressor cells and ability to prolong cardiac allograft survival in rats. Turka LA; Tanaka K; Kupiec-Weglinski JW; Milford EL; Tilney NL; Carpenter CB Transplantation; 1989 Feb; 47(2):388-90. PubMed ID: 2521965 [No Abstract] [Full Text] [Related]
13. Inhibition of allograft rejection and organ-specific autoimmune disease by anti-interleukin-2 receptor (IL-2R)-targeted immunotherapy. The action of anti-IL-2R monoclonal antibodies and synergistic effect of cyclosporin A. Diamantstein T; Mouzaki A; Osawa H; Volk HD; Hahn HJ; Kirkman RL; Strom TB; Tilney NL; Kupiec-Weglinski JW Dev Biol Stand; 1988; 69():177-84. PubMed ID: 3066671 [No Abstract] [Full Text] [Related]
14. Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy. Tellides G; Dallman MJ; Kupiec-Weglinski JW; Diamantstein T; Morris PJ Transplant Proc; 1987 Oct; 19(5):4231-3. PubMed ID: 3118538 [No Abstract] [Full Text] [Related]
15. Anti-interleukin 2 receptor monoclonal antibody therapy in rat recipients of cardiac allografts: the role of antibody isotype. Kupiec-Weglinski JW; Di Stefano R; Stunkel KG; Grutzmann R; Theisen P; Araneda D; Tilney NL; Diamantstein T Transplant Proc; 1988 Feb; 20(1 Suppl 1):272-5. PubMed ID: 3126574 [No Abstract] [Full Text] [Related]
16. Identification of IL 2R+ T cells and macrophages within rejecting rat cardiac allografts, and comparison of the effects of treatment with anti-IL 2R monoclonal antibody or cyclosporin. Hancock WW; Lord RH; Colby AJ; Diamantstein T; Rickles FR; Dijkstra C; Hogg N; Tilney NL J Immunol; 1987 Jan; 138(1):164-70. PubMed ID: 3097143 [TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta/interleukin-2-induced regulatory CD4+ T cells prolong cardiac allograft survival in rats. Watanabe M; Mencel RL; Cramer DV; Starnes VA; Barr ML J Heart Lung Transplant; 2005 Dec; 24(12):2153-9. PubMed ID: 16364865 [TBL] [Abstract][Full Text] [Related]